New Therapies

What Do Parasites Have to Do With Leukemia?

Researchers explored the possibility of using malaria as a positive tool to preventing and treating cancer in patients.


 

Parasites have been shown to have both pro- and antitumor effects. Malaria parasites ( Plasmodium spp) are among those known to have this possible “bidirectional role” in carcinogenesis, say researchers from Aix-Marseille Université in France. They reviewed the current thinking on whether malaria—a worldwide killer—can be useful in cancer prevention and treatment.

Related: Pneumatic Tube-Induced Reverse Pseudohyperkalemia in a Patient With Chronic Lymphocytic Leukemia

Positive relationships between malaria and virus-associated cancers are relatively well documented, the researchers say. Evidence suggests that malaria can alter immune responses by modulating both humoral and cell-mediated immunity. Plasmodium -related cancers are primarily lymphoproliferative, vulnerable to virus reactivation. Epstein-Barr virus (EBV), for example, has been observed in lymphatic and hematologic tumors such as Hodgkin disease and T cell lymphoma, and malaria can reactivate EBV.

In animal studies, malarial infection with Plasmodium berghei ( P berghei ) increased the rate of spontaneous leukemia. In one study, concurrent infection with P berghei increased the incidence of malignant lymphoma in mice injected with Moloney leukemogenic virus.

Related: Patterns of Initial Treatment in Veteran Patients With Chronic Lymphocytic Leukemia: A National VA Tumor Registry Study

On the other hand, Plasmodium spp also produces proteins that demonstrate certain anti-oncogenic effects, they note. The researchers suggest that using proteins in cancer treatment should be explored, adding that it’s a “safer approach than the inoculation of wild type Plasmodium.” Positive parasite-induced effects against cancers of the hematopoietic and lymphoid tissues are mentioned only for 2 species and those only in a decades-old study. Based on current knowledge, the researchers say, the antitumor effects observed are attributable to modifications to the host immune response. Thus, their characteristics and locations within the host can be highly diverse.

All in all, the researchers conclude, the growing evidence is opening intriguing pathways for using one ill to cure another.

Related: Initial Cytogenetic Features of Veteran Patients With Chronic Lymphocytic Leukemia: A National VA Tumor Registry Study

Source:
Faure E. Parasitology. 2016;143(14):1811-1823.

Recommended Reading

Hepatitis infection raises non-Hodgkin lymphoma risk in HIV patients
Federal Practitioner
Hashimoto’s Thyroiditis and Lymphoma
Federal Practitioner
Non-Hodgkin Lymphoma Death Rates Continue to Fall
Federal Practitioner
HHS Buys Growth Factor Products for Emergency Use
Federal Practitioner
Multiple Myeloma and Stroke: What’s the Risk?
Federal Practitioner